8-K
filed November 3, 2022, 7:59 PM ET
ticker MED
CIK 0000910329
earnings
confidence high
sentiment negative
materiality 0.85
Medifast Q3 revenue down 5.6%; cuts FY2022 revenue and EPS guidance on macro headwinds
MEDIFAST INC
2022-Q3 EPS reported
$10.30
revenue$1,261,332,000
- Revenue $390.4M (-5.6% YoY); net income $36.2M ($3.27 diluted EPS). Non-GAAP adjusted EPS $3.32.
- Active earning OPTA VIA Coaches 66,200 (+8.5% YoY) but revenue per coach fell 12.9% to $5,897.
- Full-year 2022 revenue guidance cut to $1.51B-$1.59B from $1.58B-$1.66B; non-GAAP EPS to $11.61-$13.05 from $12.70-$14.10.
- Gross margin 72.5% vs 74.3% prior year; cash $69.7M, zero debt; completed $100M ASR program.
- Quarterly dividend of $1.64 per share declared; Euromonitor ranked OPTA VIA #1 U.S. weight loss program by revenue.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
MEDIFAST INC reported the third quarter ended September 30, 2022 results: revenue $390.4 million, net income $36.2 million, EPS $3.27 per diluted share.
- Period
- the third quarter ended September 30, 2022
- Revenue
- $390.4 million
- Net income
- $36.2 million
- EPS
- $3.27 per diluted share
- Result
- reported results
Exact text from the filing
Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA® , today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 • Revenue of $390.4 million, with revenue per active earning coach of $5,897 • Independent active earning OPTA VIA Coaches of 66,200 • Net income of $36.2 million (non-GAAP adjusted net income of $36.8 million) • Earnings per diluted share of $3.27 (non-GAAP adjusted EPS of $3.32)
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
MEDIFAST INC reported full-year 2022 results: revenue $1.51 billion to $1.59 billion, EPS $11.61 to $13.05. Guidance lowered.
- Period
- full-year 2022
- Revenue
- $1.51 billion to $1.59 billion
- EPS
- $11.61 to $13.05
- Guidance
- lowered
- Result
- guidance update
Exact text from the filing
The company now anticipates that full-year 2022 revenue to be in the range of $1.51 billion to $1.59 billion, down from the previously announced range of $1.58 billion to $1.66 billion that was previously disclosed. The company expects full-year 2022 non-GAAP diluted EPS to be in the range of $11.61 to $13.05, down from the previously announced range of $12.70 to $14.10.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.